We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Helicobacter Pylori Immunoassays Evaluated for Efficacy

By LabMedica International staff writers
Posted on 19 Mar 2018
Helicobacter pylori are curved gram negative bacilli and have been etiologically associated with several pathogenic conditions of the stomach ranging from gastritis to gastric cancer. More...
Prevalence of H. pylori infection varies based on several factors globally and in developing countries more than 80% of the population is infected with H. pylori.

Helicobacter pylori antibody titers fall very slowly even after successful treatment. Therefore, tests detecting H. pylori antibody lack specificity and sensitivity. On the other hand, H. pylori stool antigen tests are reported as an alternative assay because of their reliability and simplicity. Serology is a widely available and inexpensive test but with low diagnostic accuracy. On the other hand, the H. pylori stool antigen (HpSA) test has been put in the market as optional technique because of its reliability and simplicity.

Medical scientists at the University of Gondar (Gondar, Ethiopia) conducted a cross sectional study on patients with dyspepsia from February to March 2015 attending the medical outpatient department of the University Hospital. Stool and blood specimens were collected from each patient for serologic tests. The blood was centrifuged until serum was separated and stored at –20 °C. The stool specimens were also stored at –20 °C until the laboratory tests were performed.

A total of 201 dyspeptic patients were included in the study of which 140 (69.7%) were males and 60 (30.3%) were females. The age of the participants ranged from 7 to 85 years with a mean age of 29.5 ±14.85 years. The team evaluated the performance of SD BIOLINE H. pylori Ag rapid test with reference to the commercially available SD BIOLINE H. pylori Ag ELISA and the EZ- STEP ELISA tests. The dBest H. pylori Test Disk was also evaluated.

The team found that 75 (37.1%) of the participants were positive by the SD BIOLINE H. pylori Ag rapid test, while 92 (45.8%) were positive by the SD H. pylori Ag ELISA. The EZ-STEP H. pylori Ag ELISA detected 81 (40.3%) of the samples as positives for H. pylori infection. On the other hand, 68 (33.8%) were positive using both ELISA tests. The dBest H. pylori Test disk detected 143(71.1%) of the samples as positive. The sensitivity, specificity, positive and negative predictive values of the SD BIOLINE H. pylori Ag rapid test were: 95.6%, 92.5%, 86.7%, and 97.6%, respectively.

The authors concluded that The SD BIOLINE H. pylori Ag rapid test has a much better sensitivity, specificity and predictive values compared to the currently available antibody test in the market, in Ethiopia. Therefore, the SD BIOLINE H. pylori Ag rapid stool test could be used to diagnose active H. pylori infection before the commencement of eradication therapy. The study was published on March 5, 2018, in the journal BMC Clinical Pathology.

Related Links:
University of Gondar


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.